Business
Novavax to Participate in Cowen's 42nd Annual Health Care Conference
GAITHERSBURG, Md., March 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing
About this update from Novavax, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., March 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Cowen's 42nd Annual Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.\nConference Details:\nFireside Chat\nDate:\nTuesday, March 8, 2022\nTime:\n9:50 – 10:20 a.m. Eastern Standard Time (EST)\nCowen Moderator:\nGeorgi Yordanov, Ph.D.\nNovavax participants:\nFilip Dubovsky, M.D., Executive Vice President, Chief Medical Officer and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer\nConference\nEvent:\nInvestor Meetings\nDate:\nTuesday, March 8, 2022\nA replay of the recorded fireside session will be available through the events page of the Company's website at ir.novavax.com for 90 days.\nAbout Novavax\nNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu, its quadrivalent influenza investigational vaccine candidate. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.\nFor more information, visit www.novavax.com and connect with us on Twitter, LinkedIn, Instagram and Facebook.\nContacts: InvestorsNovavax, Inc. Erika Schultz | [email protected]\nSolebury TroutAlexandra Roy | 617-221-9197aroy@so...